Is Eli Lilly over valued?

Intrinsic Value. The intrinsic value of one LLY stock under the Base Case scenario is 356.76 USD. Compared to the current market price of 931.58 USD, Eli Lilly and Co is Overvalued by 62% .

What is the price outlook for Eli Lilly stock?

Stock Price Targets High $1,150.00 Median $1,012.50 Low $640.00 Average $993.38 Current Price $908.05

Is LLY a good buy now?

Broker Rating. Eli Lilly currently has an average brokerage recommendation (ABR) of 1.11 on a scale of 1 to 5 (Strong Buy to Strong Sell) , calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 23 brokerage firms. The current ABR compares to an ABR of 1.20 a month ago based on 22 recommendations.

What is the Eli Lilly controversy?

In 2018, the Minnesota Attorney General sued Eli Lilly, Sanofi, and one additional insulin manufacturer alleging they deceptively priced their insulin products , which caused uninsured and underinsured Minnesotans to pay astronomically high out-of-pocket costs based on the list price of the drugs.

Who are the largest shareholders in Eli Lilly?

Largest shareholders include Lilly Endowment Inc, Vanguard Group Inc, BlackRock Inc., Pnc Financial Services Group, Inc., State Street Corp, Fmr Llc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Capital World Investors, Price T Rowe Associates Inc /md/, and VFINX - Vanguard 500 Index Fund Investor ...

How much will Eli Lilly stock cost in 2025?

Eli Lilly Price Forecast and Prediction for 2030: Year Price Target % Change From Current Price 2025 $1140.00 Upside of 22.56% 2026 $1250.00 Upside of 34.39% 2027 $1520.00 Upside of 63.41% 2028 $1300.00 Upside of 39.76% 2 more rows 4 days ago

What is the target price for LLY in 2024?

At the end 1048 dollars , change for August 29.5%. Eli Lilly stock prediction for September 2024. The forecast for beginning 1048 dollars. Maximum price 1286, minimum 891.

Why is Eli Lilly's valuation so high?

Looking at Q2, Eli Lilly's revenue of $11.3 billion reflected a solid 36% y-o-y growth. This can be attributed to market share gains for some of its drugs , including Mounjaro, Verzenio, and Zepbound. Mounjaro saw a massive 3x surge in sales to $3.1 billion. Verzenio sales were also up a solid 44% y-o-y to $1.3 billion.

Why is Eli Lilly going up so much?

Eli Lilly (LLY) stock surged in early August, buoyed by second-quarter outperformance from its diabetes and obesity treatments Mounjaro and Zepbound . Mounjaro sales rocketed more than 215% year over year. The type 2 diabetes treatment is Lilly's biggest moneymaker.

What is the fair value of Eli Lilly?

As of 2024-08-11, the Fair Value of Eli Lilly and Co (LLY) is 181.91 USD . This value is based on the Peter Lynch's Fair Value formula. With the current market price of 891.68 USD, the upside of Eli Lilly and Co is -79.6%.

Has Eli Lilly stock risen 400% in 3 years?

This significant rise for Eli Lilly can be attributed to: 1. a significant 273% rise in the company's P/S ratio to 23x now, versus 6x in late 2020 . 2. a 39% jump in the Eli Lilly's revenue from $25 billion to $39 billion over this period, partly offset by 3.

Roche (OTCMKTS:RHHVF) vs. Eli Lilly and Company (NYSE:LLY) Critical Contrast (2024)

Posted by Defense World Staff on Aug 19th, 2024

Roche (OTCMKTS:RHHVF – Get Free Report) and Eli Lilly and Company (NYSE:LLY – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Earnings & Valuation

This table compares Roche and Eli Lilly and Company’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roche	N/A	N/A	N/A	$10.81	29.76
Eli Lilly and Company	$38.92 billion	22.52	$5.24 billion	$6.79	135.81

Eli Lilly and Company has higher revenue and earnings than Roche. Roche is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Dividends

Roche pays an annual dividend of $7.80 per share and has a dividend yield of 2.4%. Eli Lilly and Company pays an annual dividend of $5.20 per share and has a dividend yield of 0.6%. Roche pays out 72.2% of its earnings in the form of a dividend. Eli Lilly and Company pays out 76.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Roche is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares Roche and Eli Lilly and Company’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Roche	N/A	N/A	N/A
Eli Lilly and Company	17.08%	56.98%	10.94%

Analyst Ratings

This is a summary of recent recommendations for Roche and Eli Lilly and Company, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roche	0	0	0	0	N/A
Eli Lilly and Company	0	2	16	0	2.89

Insider & Institutional Ownership

29.0% of Roche shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Eli Lilly and Company beats Roche on 9 of the 12 factors compared between the two stocks.

About Roche

(Get Free Report)

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.